Trials / Active Not Recruiting
Active Not RecruitingNCT05888831
A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors
A Phase 1/2 Study of BMS-986449 Alone and in Combination With Nivolumab in Participants With Advanced Solid Tumors
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of BMS-986449 alone and in combination with nivolumab in participants with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986449 | Specified dose on specified days |
| DRUG | Nivolumab | Specified dose on specified days |
Timeline
- Start date
- 2023-06-06
- Primary completion
- 2026-09-30
- Completion
- 2026-09-30
- First posted
- 2023-06-05
- Last updated
- 2025-06-11
Locations
20 sites across 6 countries: United States, Belgium, France, Italy, Netherlands, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05888831. Inclusion in this directory is not an endorsement.